阿瑞吡坦联合昂丹司琼及地塞米松防治直肠癌患者术后化疗相关性恶心呕吐临床观察  

Clinical Observation of Triple Therapy with Aprepitant,Ondansetron and Dexamethasone on Prevention of Adjuvant Chemotherapy Induced Nausea and Vomiting for Post-operative Patients with Rectal Carcinoma

作　　者：潘国华 徐媛 胡萨萨[1] 李鹏飞 余资 袁达伟[3] 

机构地区：[1]西安交通大学第一附属医院药学部,西安710061 [2]长安医院药剂科 [3]西安交通大学第一附属医院肿瘤外科

出　　处：《药物流行病学杂志》2017年第11期725-728,共4页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:探讨阿瑞吡坦联合昂丹司琼及地塞米松防治直肠癌患者术后mFOLFOX6方案化疗相关性恶心呕吐的临床疗效。方法:122例接受术后mFOLFOX6方案化疗的直肠癌患者随机分入观察组(阿瑞吡坦+昂丹司琼+地塞米松)和对照组(昂丹司琼+地塞米松)进行预防性止吐。记录患者恶心、呕吐及其他不良反应,并评估化疗相关性恶心呕吐对患者生活质量的影响。结果:观察组急性呕吐和延迟性呕吐控制有效率分别为80.0%和83.3%,均显著优于对照组(P<0.05)。两组恶心控制有效率差异无统计学意义(P>0.05)。观察组患者生活质量评分显著高于对照组(P<0.01),且观察组对生活质量产生负面影响的人数明显少于对照组(P<0.01)。结论:阿瑞吡坦联合昂丹司琼及地塞米松对术后mFOLFOX6方案化疗的直肠癌患者发生呕吐的控制作用显著,同时能改善患者的生活质量,且未造成更多不良反应。Objective：To determine the clinical effects of triple therapy with aprepitant, ondansetron and dexamethasone on nausea and vomiting caused by mFOLFOX6 chemotherapy regimen for post-operative patients with rectal carcinoma. nethods：A total of 122 post-operative patients with rectal carcinoma who received mFOLFOX6 chemotherapy, were assigned by sortition randomization method into observation group （ Aprepitant ＋ Ondansetron ＋ Dexamethasone） and control group （ Ondansetron ＋ Dexamethasone） for the prevention of nausea and vomiting. The nausea, vomiting, and other adverse effects were observed, as well as the impact of the quality of life of patients of chemotherapy associated with nausea and vomiting was evaluated. Results： The effective rate of acute and delayed vomiting in observation group was 80.0% and 83.3% respectively, both of which were significantly better than the control group （P 〈 0. 05 ）. Nausea control rate revealed no significant differences between the two groups （ P 〉 0.05 ）. The functional living index-emesis of observation group was significantly higher than that of the control group （P 〈 0.01 ）, and the people who suffered negative effect in the observation group was significantly fewer than that in the control group （P 〈 0.01 ）. Conclusion：The triple therapy with aprepitant, ondansetron and dexamethasone could effectively prevent vomiting caused by mFOLFOX6 chemotherapy regimen in post-operative patients with rectal carcinoma. It could improve the quality of life of these patients with mild adverse reactions.

关 键 词：阿瑞吡坦 直肠癌 化疗相关性恶心呕吐 MFOLFOX6 生活质量 

分 类 号：R979.1[医药卫生—药品]